Hari, P
Mateos, M-V
Abonour, R
Knop, S
Bensinger, W
Ludwig, H
Song, K
Hajek, R
Moreau, P
Siegel, D S
Feng, S
Obreja, M
Aggarwal, S K
Iskander, K
Goldschmidt, H
Article History
Received: 29 November 2016
Revised: 9 March 2017
Accepted: 3 April 2017
First Online: 25 April 2017
Competing interests
: MVM has received personal fees from Janssen, Celgene, BMS, Amgen and Takeda. PH has received grants and personal fees from Amgen, Celgene, Takeda, Spectrum and BMS. RA has no relationships to disclose. SK has received personal fees from Amgen, Celgene, Bristol-Myers Squibb and Onyx. WB has received grants and personal fees from Amgen and Celgene. HL has received grants from Takeda, Amgen and Janssen and personal fees from Takeda, Celgene, Amgen and Bristol-Myers Squibb. KS has received personal fees from Amgen, Celgene, Janssen and Takeda. RH has served as a consultant for and received honoraria from Janssen, Celgene and Amgen. PM has served as a consultant for and received honoraria from Celgene, Onyx, Janssen, Novartis and Millennium. DSS has served on the speakers’ bureau for and received honoraria from Celgene, Millennium and Onyx. SF, MO, SKA and KI are employees at Amgen. HG has served as a consultant for Amgen, Celgene, Janssen, Takeda, Novartis, Onyx and BMS and has received research funding and honoraria from Janssen, Celgene, Novartis, Chugai and Millennium.